We are proud to have represented our long-standing client BioLineRX (NASDAQ: BLRX) (TASE: BLRX) in establishing a joint venture with Hemispherian AS of Norway to develop GLIX1, a first-in-class, oral small molecule targeting DNA damage response in Glioblastoma (GBM) and other cancers. The cross-border transaction involved the negotiation and drafting of complex intellectual property and technology asset transfer agreements, as well as joint venture agreements setting out governance, management, and investment frameworks.
This promising international venture once again highlights Arnon, Tadmor-Levy’s deep experience in such transaction, as well as our dedication and commitment to serving as trusted advisors to innovative visionaries.
Congratulations to Daniel Green, Simon Weintraub, Nataly Margalit, Leah Grumet, Idan Adar and Shmulie (Samuel) Kuperstok for their outstanding contributions.
We wish our friends at BioLineRx and Hemispherian lots of success implementing this important venture!
To read the full article, click here >>
